Eintrag weiter verarbeiten
A phase II study for metabolic in vivo response monitoring with sequential 18FDG-PET-CT during treatment with the EGFR-monoclonal-antibody cetuximab in metastatic colorectal cancer...
Gespeichert in:
| Veröffentlicht in: | BMC cancer 12(2012) Artikel-Nummer 108, 6 Seiten |
|---|---|
| Personen und Körperschaften: | , , , , , , , , |
| Titel: | A phase II study for metabolic in vivo response monitoring with sequential 18FDG-PET-CT during treatment with the EGFR-monoclonal-antibody cetuximab in metastatic colorectal cancer: the Heidelberg REMOTUX trial/ Anne Katrin Berger, Carl von Gall, Ulrich Abel, Stefan Delorme, Matthias Kloor, Jennifer Ose, Tim Frederik Weber, Annika Stange, Georg Martin Haag, Uwe Haberkorn, Florian Lordick, Dirk Jäger |
| Format: | E-Book-Kapitel |
| Sprache: | Englisch |
| veröffentlicht: |
22 March 2012
|
| Gesamtaufnahme: |
: BMC cancer, 12(2012) Artikel-Nummer 108, 6 Seiten
, volume:12 |
| Schlagwörter: | |
| Quelle: | Verbunddaten SWB Lizenzfreie Online-Ressourcen |
| LEADER | 04549caa a2200781 4500 | ||
|---|---|---|---|
| 001 | 0-1572358572 | ||
| 003 | DE-627 | ||
| 005 | 20220814123156.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 180425s2012 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1186/1471-2407-12-108 |2 doi | |
| 035 | |a (DE-627)1572358572 | ||
| 035 | |a (DE-576)502358572 | ||
| 035 | |a (DE-599)BSZ502358572 | ||
| 035 | |a (OCoLC)1341007762 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 100 | 1 | |a Berger, Anne Katrin |d 1978- |e VerfasserIn |0 (DE-588)132177889 |0 (DE-627)519022424 |0 (DE-576)298988380 |4 aut | |
| 245 | 1 | 2 | |a A phase II study for metabolic in vivo response monitoring with sequential 18FDG-PET-CT during treatment with the EGFR-monoclonal-antibody cetuximab in metastatic colorectal cancer |b the Heidelberg REMOTUX trial |c Anne Katrin Berger, Carl von Gall, Ulrich Abel, Stefan Delorme, Matthias Kloor, Jennifer Ose, Tim Frederik Weber, Annika Stange, Georg Martin Haag, Uwe Haberkorn, Florian Lordick, Dirk Jäger |
| 264 | 1 | |c 22 March 2012 | |
| 300 | |a 6 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 25.04.2018 | ||
| 520 | |a The epidermal growth factor receptor monoclonal antibody cetuximab has proven activity in metastatic colorectal cancer. To date, the mechanisms of action are not completely understood. Especially the impact on tumor glucose metabolism, or tumor vascularization remains largely unclear. The understanding of mechanisms such as early changes in tumor metabolism is of clinical importance since there may be a substantial influence on choice and sequence of drug combinations. Early signals of response to cetuximab may prove useful to identify patients having a relevant clinical treatment benefit. The objective of this trial is to evaluate the predictive relevance of the relative change in 18 F-Fluorodeoxyglucose tumor uptake for early clinical response during short-term single agent treatment with cetuximab. Early clinical response will be routinely measured according to the response evaluation criteria in solid tumors. Accompanying research includes cytokine immune monitoring and analysis of tumor proteins and tumor genes. | ||
| 650 | 4 | |a 18F-FDG PET CT | |
| 650 | 4 | |a Cetuximab | |
| 650 | 4 | |a Colorectal cancer | |
| 650 | 4 | |a Metabolic imaging | |
| 650 | 4 | |a Metastases | |
| 700 | 1 | |a Abel, Ulrich |d 1952- |e VerfasserIn |0 (DE-588)14287552X |0 (DE-627)640555403 |0 (DE-576)333774582 |4 aut | |
| 700 | 1 | |a Kloor, Matthias |d 1972- |e VerfasserIn |0 (DE-588)124552803 |0 (DE-627)363416609 |0 (DE-576)294228616 |4 aut | |
| 700 | 1 | |a Ose, Jennifer |d 1979- |e VerfasserIn |0 (DE-588)1136678018 |0 (DE-627)893435805 |0 (DE-576)490759270 |4 aut | |
| 700 | 1 | |a Weber, Tim |d 1977- |e VerfasserIn |0 (DE-588)133392694 |0 (DE-627)544045017 |0 (DE-576)299816613 |4 aut | |
| 700 | 1 | |a Stange, Annika |e VerfasserIn |0 (DE-588)1137859814 |0 (DE-627)895137607 |0 (DE-576)49178001X |4 aut | |
| 700 | 1 | |a Haag, Georg Martin |d 1979- |e VerfasserIn |0 (DE-588)133390934 |0 (DE-627)544043863 |0 (DE-576)29981548X |4 aut | |
| 700 | 1 | |a Haberkorn, Uwe |d 1959- |e VerfasserIn |0 (DE-588)1022913905 |0 (DE-627)717331245 |0 (DE-576)366166352 |4 aut | |
| 700 | 1 | |a Jäger, Dirk |d 1964- |e VerfasserIn |0 (DE-588)1032507535 |0 (DE-627)738505323 |0 (DE-576)380074125 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t BMC cancer |d London : BioMed Central, 2001 |g 12(2012) Artikel-Nummer 108, 6 Seiten |h Online-Ressource |w (DE-627)326643710 |w (DE-600)2041352-X |w (DE-576)107014645 |x 1471-2407 |7 nnns |
| 773 | 1 | 8 | |g volume:12 |g year:2012 |g extent:6 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1186/1471-2407-12-108 |x Verlag |x Resolving-System |z kostenfrei |3 Volltext |
| 856 | 4 | 0 | |u https://doi.org/10.1186/1471-2407-12-108 |x Verlag |z kostenfrei |3 Volltext |
| 936 | u | w | |d 12 |j 2012 |g 6 |y 12(2012) Artikel-Nummer 108, 6 Seiten |
| 951 | |a AR | ||
| 856 | 4 | 0 | |u http://dx.doi.org/10.1186/1471-2407-12-108 |9 LFER |
| 852 | |a LFER |z 2018-05-17T00:00:00Z | ||
| 970 | |c OD | ||
| 971 | |c EBOOK | ||
| 972 | |c EBOOK | ||
| 973 | |c Aufsatz | ||
| 935 | |a lfer | ||
| 900 | |a Möller, Jennifer | ||
| 900 | |a Weber, Tim Frederik | ||
| 900 | |a Weber, T.F. | ||
| 900 | |a Weber, T. F. | ||
| 900 | |a Haag, Georg-Martin | ||
| 900 | |a Haag, Martin | ||
| 900 | |a Jäger, D. | ||
| 900 | |a Jaeger, Dirk | ||
| 900 | |a Kloor, Matthias Johannes | ||
| 900 | |a Abel, Ulrich R. | ||
| 900 | |a Abel, U. R. | ||
| 900 | |a Haberhorn, Uwe | ||
| 900 | |a Haberkorn, Uwe L. | ||
| 900 | |a Haberkorn, U. | ||
| 951 | |b XA-DE | ||
| 980 | |a 1572358572 |b 0 |k 1572358572 |o 502358572 |c lfer | ||
| openURL |
url_ver=Z39.88-2004&ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fvufind.svn.sourceforge.net%3Agenerator&rft.title=A+phase+II+study+for+metabolic+in+vivo+response+monitoring+with+sequential+18FDG-PET-CT+during+treatment+with+the+EGFR-monoclonal-antibody+cetuximab+in+metastatic+colorectal+cancer%3A+the+Heidelberg+REMOTUX+trial&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Adc&rft.creator=Berger%2C+Anne+Katrin&rft.pub=&rft.format=Journal&rft.language=English&rft.issn=1471-2407 |
|---|
| _version_ | 1757949477571788800 |
|---|---|
| access_facet | Electronic Resources |
| author | Berger, Anne Katrin, Abel, Ulrich, Kloor, Matthias, Ose, Jennifer, Weber, Tim, Stange, Annika, Haag, Georg Martin, Haberkorn, Uwe, Jäger, Dirk |
| author_facet | Berger, Anne Katrin, Abel, Ulrich, Kloor, Matthias, Ose, Jennifer, Weber, Tim, Stange, Annika, Haag, Georg Martin, Haberkorn, Uwe, Jäger, Dirk |
| author_role | aut, aut, aut, aut, aut, aut, aut, aut, aut |
| author_sort | Berger, Anne Katrin 1978- |
| author_variant | a k b ak akb, u a ua, m k mk, j o jo, t w tw, a s as, g m h gm gmh, u h uh, d j dj |
| callnumber-sort | |
| collection | lfer |
| container_reference | 12(2012) Artikel-Nummer 108, 6 Seiten |
| container_title | BMC cancer |
| contents | The epidermal growth factor receptor monoclonal antibody cetuximab has proven activity in metastatic colorectal cancer. To date, the mechanisms of action are not completely understood. Especially the impact on tumor glucose metabolism, or tumor vascularization remains largely unclear. The understanding of mechanisms such as early changes in tumor metabolism is of clinical importance since there may be a substantial influence on choice and sequence of drug combinations. Early signals of response to cetuximab may prove useful to identify patients having a relevant clinical treatment benefit. The objective of this trial is to evaluate the predictive relevance of the relative change in 18 F-Fluorodeoxyglucose tumor uptake for early clinical response during short-term single agent treatment with cetuximab. Early clinical response will be routinely measured according to the response evaluation criteria in solid tumors. Accompanying research includes cytokine immune monitoring and analysis of tumor proteins and tumor genes. |
| ctrlnum | (DE-627)1572358572, (DE-576)502358572, (DE-599)BSZ502358572, (OCoLC)1341007762 |
| doi_str_mv | 10.1186/1471-2407-12-108 |
| facet_avail | Online, Free |
| finc_class_facet | not assigned |
| finc_id_str | 0021094809 |
| footnote | Gesehen am 25.04.2018 |
| format | ElectronicBookComponentPart |
| format_access_txtF_mv | Article, E-Article |
| format_de105 | Ebook |
| format_de14 | Article, E-Article |
| format_de15 | Article, E-Article |
| format_del152 | Buch |
| format_detail_txtF_mv | text-online-monograph-child |
| format_dezi4 | e-Book |
| format_finc | Article, E-Article |
| format_legacy | ElectronicBookPart |
| format_strict_txtF_mv | E-Article |
| geogr_code | not assigned |
| geogr_code_person | Germany |
| hierarchy_parent_id | 0-326643710 |
| hierarchy_parent_title | BMC cancer |
| hierarchy_sequence | 12(2012) Artikel-Nummer 108, 6 Seiten |
| hierarchy_top_id | 0-326643710 |
| hierarchy_top_title | BMC cancer |
| id | 0-1572358572 |
| illustrated | Not Illustrated |
| imprint | 22 March 2012 |
| imprint_str_mv | 22 March 2012 |
| institution | DE-D117, DE-105, LFER, DE-Ch1, DE-15, DE-14, DE-Zwi2 |
| is_hierarchy_id | 0-1572358572 |
| is_hierarchy_title | A phase II study for metabolic in vivo response monitoring with sequential 18FDG-PET-CT during treatment with the EGFR-monoclonal-antibody cetuximab in metastatic colorectal cancer: the Heidelberg REMOTUX trial |
| isil_str_mv | LFER |
| issn | 1471-2407 |
| kxp_id_str | 1572358572 |
| language | English |
| last_indexed | 2023-02-16T01:34:26.025Z |
| local_heading_facet_dezwi2 | 18F-FDG PET CT, Cetuximab, Colorectal cancer, Metabolic imaging, Metastases |
| marc024a_ct_mv | 10.1186/1471-2407-12-108 |
| match_str | berger2012aphaseiistudyformetabolicinvivoresponsemonitoringwithsequential18fdgpetctduringtreatmentwiththeegfrmonoclonalantibodycetuximabinmetastaticcolorectalcancertheheidelbergremotuxtrial |
| mega_collection | Verbunddaten SWB, Lizenzfreie Online-Ressourcen |
| misc_de105 | EBOOK |
| multipart_link | 107014645 |
| multipart_part | (107014645)12(2012) Artikel-Nummer 108, 6 Seiten |
| names_id_str_mv | (DE-588)132177889, (DE-627)519022424, (DE-576)298988380, (DE-588)14287552X, (DE-627)640555403, (DE-576)333774582, (DE-588)124552803, (DE-627)363416609, (DE-576)294228616, (DE-588)1136678018, (DE-627)893435805, (DE-576)490759270, (DE-588)133392694, (DE-627)544045017, (DE-576)299816613, (DE-588)1137859814, (DE-627)895137607, (DE-576)49178001X, (DE-588)133390934, (DE-627)544043863, (DE-576)29981548X, (DE-588)1022913905, (DE-627)717331245, (DE-576)366166352, (DE-588)1032507535, (DE-627)738505323, (DE-576)380074125 |
| oclc_num | 1341007762 |
| physical | 6 |
| publishDate | 22 March 2012 |
| publishDateSort | 2012 |
| publishPlace | |
| publisher | |
| record_format | marcfinc |
| record_id | 502358572 |
| recordtype | marcfinc |
| rvk_facet | No subject assigned |
| source_id | 0 |
| spelling | Berger, Anne Katrin 1978- VerfasserIn (DE-588)132177889 (DE-627)519022424 (DE-576)298988380 aut, A phase II study for metabolic in vivo response monitoring with sequential 18FDG-PET-CT during treatment with the EGFR-monoclonal-antibody cetuximab in metastatic colorectal cancer the Heidelberg REMOTUX trial Anne Katrin Berger, Carl von Gall, Ulrich Abel, Stefan Delorme, Matthias Kloor, Jennifer Ose, Tim Frederik Weber, Annika Stange, Georg Martin Haag, Uwe Haberkorn, Florian Lordick, Dirk Jäger, 22 March 2012, 6, Text txt rdacontent, Computermedien c rdamedia, Online-Ressource cr rdacarrier, Gesehen am 25.04.2018, The epidermal growth factor receptor monoclonal antibody cetuximab has proven activity in metastatic colorectal cancer. To date, the mechanisms of action are not completely understood. Especially the impact on tumor glucose metabolism, or tumor vascularization remains largely unclear. The understanding of mechanisms such as early changes in tumor metabolism is of clinical importance since there may be a substantial influence on choice and sequence of drug combinations. Early signals of response to cetuximab may prove useful to identify patients having a relevant clinical treatment benefit. The objective of this trial is to evaluate the predictive relevance of the relative change in 18 F-Fluorodeoxyglucose tumor uptake for early clinical response during short-term single agent treatment with cetuximab. Early clinical response will be routinely measured according to the response evaluation criteria in solid tumors. Accompanying research includes cytokine immune monitoring and analysis of tumor proteins and tumor genes., 18F-FDG PET CT, Cetuximab, Colorectal cancer, Metabolic imaging, Metastases, Abel, Ulrich 1952- VerfasserIn (DE-588)14287552X (DE-627)640555403 (DE-576)333774582 aut, Kloor, Matthias 1972- VerfasserIn (DE-588)124552803 (DE-627)363416609 (DE-576)294228616 aut, Ose, Jennifer 1979- VerfasserIn (DE-588)1136678018 (DE-627)893435805 (DE-576)490759270 aut, Weber, Tim 1977- VerfasserIn (DE-588)133392694 (DE-627)544045017 (DE-576)299816613 aut, Stange, Annika VerfasserIn (DE-588)1137859814 (DE-627)895137607 (DE-576)49178001X aut, Haag, Georg Martin 1979- VerfasserIn (DE-588)133390934 (DE-627)544043863 (DE-576)29981548X aut, Haberkorn, Uwe 1959- VerfasserIn (DE-588)1022913905 (DE-627)717331245 (DE-576)366166352 aut, Jäger, Dirk 1964- VerfasserIn (DE-588)1032507535 (DE-627)738505323 (DE-576)380074125 aut, Enthalten in BMC cancer London : BioMed Central, 2001 12(2012) Artikel-Nummer 108, 6 Seiten Online-Ressource (DE-627)326643710 (DE-600)2041352-X (DE-576)107014645 1471-2407 nnns, volume:12 year:2012 extent:6, http://dx.doi.org/10.1186/1471-2407-12-108 Verlag Resolving-System kostenfrei Volltext, https://doi.org/10.1186/1471-2407-12-108 Verlag kostenfrei Volltext, http://dx.doi.org/10.1186/1471-2407-12-108 LFER, LFER 2018-05-17T00:00:00Z |
| spellingShingle | Berger, Anne Katrin, Abel, Ulrich, Kloor, Matthias, Ose, Jennifer, Weber, Tim, Stange, Annika, Haag, Georg Martin, Haberkorn, Uwe, Jäger, Dirk, A phase II study for metabolic in vivo response monitoring with sequential 18FDG-PET-CT during treatment with the EGFR-monoclonal-antibody cetuximab in metastatic colorectal cancer: the Heidelberg REMOTUX trial, The epidermal growth factor receptor monoclonal antibody cetuximab has proven activity in metastatic colorectal cancer. To date, the mechanisms of action are not completely understood. Especially the impact on tumor glucose metabolism, or tumor vascularization remains largely unclear. The understanding of mechanisms such as early changes in tumor metabolism is of clinical importance since there may be a substantial influence on choice and sequence of drug combinations. Early signals of response to cetuximab may prove useful to identify patients having a relevant clinical treatment benefit. The objective of this trial is to evaluate the predictive relevance of the relative change in 18 F-Fluorodeoxyglucose tumor uptake for early clinical response during short-term single agent treatment with cetuximab. Early clinical response will be routinely measured according to the response evaluation criteria in solid tumors. Accompanying research includes cytokine immune monitoring and analysis of tumor proteins and tumor genes., 18F-FDG PET CT, Cetuximab, Colorectal cancer, Metabolic imaging, Metastases |
| swb_id_str | 502358572 |
| title | A phase II study for metabolic in vivo response monitoring with sequential 18FDG-PET-CT during treatment with the EGFR-monoclonal-antibody cetuximab in metastatic colorectal cancer: the Heidelberg REMOTUX trial |
| title_auth | A phase II study for metabolic in vivo response monitoring with sequential 18FDG-PET-CT during treatment with the EGFR-monoclonal-antibody cetuximab in metastatic colorectal cancer the Heidelberg REMOTUX trial |
| title_full | A phase II study for metabolic in vivo response monitoring with sequential 18FDG-PET-CT during treatment with the EGFR-monoclonal-antibody cetuximab in metastatic colorectal cancer the Heidelberg REMOTUX trial Anne Katrin Berger, Carl von Gall, Ulrich Abel, Stefan Delorme, Matthias Kloor, Jennifer Ose, Tim Frederik Weber, Annika Stange, Georg Martin Haag, Uwe Haberkorn, Florian Lordick, Dirk Jäger |
| title_fullStr | A phase II study for metabolic in vivo response monitoring with sequential 18FDG-PET-CT during treatment with the EGFR-monoclonal-antibody cetuximab in metastatic colorectal cancer the Heidelberg REMOTUX trial Anne Katrin Berger, Carl von Gall, Ulrich Abel, Stefan Delorme, Matthias Kloor, Jennifer Ose, Tim Frederik Weber, Annika Stange, Georg Martin Haag, Uwe Haberkorn, Florian Lordick, Dirk Jäger |
| title_full_unstemmed | A phase II study for metabolic in vivo response monitoring with sequential 18FDG-PET-CT during treatment with the EGFR-monoclonal-antibody cetuximab in metastatic colorectal cancer the Heidelberg REMOTUX trial Anne Katrin Berger, Carl von Gall, Ulrich Abel, Stefan Delorme, Matthias Kloor, Jennifer Ose, Tim Frederik Weber, Annika Stange, Georg Martin Haag, Uwe Haberkorn, Florian Lordick, Dirk Jäger |
| title_in_hierarchy | A phase II study for metabolic in vivo response monitoring with sequential 18FDG-PET-CT during treatment with the EGFR-monoclonal-antibody cetuximab in metastatic colorectal cancer: the Heidelberg REMOTUX trial / Anne Katrin Berger, Carl von Gall, Ulrich Abel, Stefan Delorme, Matthias Kloor, Jennifer Ose, Tim Frederik Weber, Annika Stange, Georg Martin Haag, Uwe Haberkorn, Florian Lordick, Dirk Jäger, |
| title_short | A phase II study for metabolic in vivo response monitoring with sequential 18FDG-PET-CT during treatment with the EGFR-monoclonal-antibody cetuximab in metastatic colorectal cancer |
| title_sort | phase ii study for metabolic in vivo response monitoring with sequential 18fdg pet ct during treatment with the egfr monoclonal antibody cetuximab in metastatic colorectal cancer the heidelberg remotux trial |
| title_sub | the Heidelberg REMOTUX trial |
| topic | 18F-FDG PET CT, Cetuximab, Colorectal cancer, Metabolic imaging, Metastases |
| topic_facet | 18F-FDG PET CT, Cetuximab, Colorectal cancer, Metabolic imaging, Metastases |
| url | http://dx.doi.org/10.1186/1471-2407-12-108, https://doi.org/10.1186/1471-2407-12-108 |